MX346412B - Composiciones inhibidoras virales para uso terapeutico in vivo que comprende una combinacion de (-)-carvona, geraniol y un componente adicional de aceites esenciales. - Google Patents

Composiciones inhibidoras virales para uso terapeutico in vivo que comprende una combinacion de (-)-carvona, geraniol y un componente adicional de aceites esenciales.

Info

Publication number
MX346412B
MX346412B MX2012010949A MX2012010949A MX346412B MX 346412 B MX346412 B MX 346412B MX 2012010949 A MX2012010949 A MX 2012010949A MX 2012010949 A MX2012010949 A MX 2012010949A MX 346412 B MX346412 B MX 346412B
Authority
MX
Mexico
Prior art keywords
carvone
geraniol
combination
essential oil
therapeutic use
Prior art date
Application number
MX2012010949A
Other languages
English (en)
Other versions
MX2012010949A (es
Inventor
Coppens Christine
Original Assignee
Cesa Alliance S A *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346412(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cesa Alliance S A * filed Critical Cesa Alliance S A *
Publication of MX2012010949A publication Critical patent/MX2012010949A/es
Publication of MX346412B publication Critical patent/MX346412B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una composición antiviral que comprende los siguientes componentes: R-(-)-2-metil-5-(prop-1-en-2 -il)- ciclohex-2-enona (también llamada (-) carvona) y S-(+)-2-metil- 5-(prop-1- en-2-il)-ciclohex-2-enona (también llamada (+) carvona) y (2E)-3,7- dimetilocta-2,6- dien-1-ol (también llamado trans-geraniol) en combinación con al menos un componente más elegido entre componentes de aceites esenciales para uso en el tratamiento y prevención de enfermedades provocadas por virus envueltos en ADN, virus no envueltos en ADN, virus envueltos en ARN y virus no envueltos en ARN.
MX2012010949A 2010-03-26 2011-03-28 Composiciones inhibidoras virales para uso terapeutico in vivo que comprende una combinacion de (-)-carvona, geraniol y un componente adicional de aceites esenciales. MX346412B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10157930A EP2368547B1 (en) 2010-03-26 2010-03-26 Antiviral compositions comprising geraniol and carvone
PCT/EP2011/054758 WO2011117424A1 (en) 2010-03-26 2011-03-28 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component

Publications (2)

Publication Number Publication Date
MX2012010949A MX2012010949A (es) 2013-01-29
MX346412B true MX346412B (es) 2017-03-17

Family

ID=42102951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010949A MX346412B (es) 2010-03-26 2011-03-28 Composiciones inhibidoras virales para uso terapeutico in vivo que comprende una combinacion de (-)-carvona, geraniol y un componente adicional de aceites esenciales.

Country Status (35)

Country Link
US (2) US8980945B2 (es)
EP (2) EP2368547B1 (es)
JP (1) JP5342085B2 (es)
KR (1) KR101340260B1 (es)
CN (1) CN102946876B (es)
AU (1) AU2011231511B2 (es)
BR (1) BR112012024260B1 (es)
CA (1) CA2790087C (es)
CL (1) CL2012002606A1 (es)
CO (1) CO6602166A2 (es)
CY (3) CY1113449T1 (es)
DK (2) DK2368547T3 (es)
EA (1) EA025278B9 (es)
ES (2) ES2392938T3 (es)
HK (1) HK1176019A1 (es)
HR (2) HRP20120964T1 (es)
HU (1) HUE026121T2 (es)
IL (1) IL222048A (es)
LU (1) LU91805B1 (es)
MA (1) MA34074B1 (es)
ME (1) ME02035B (es)
MX (1) MX346412B (es)
MY (2) MY153104A (es)
NZ (1) NZ602602A (es)
PE (2) PE20130065A1 (es)
PL (2) PL2368547T3 (es)
PT (2) PT2368547E (es)
RS (2) RS52544B (es)
SG (1) SG184039A1 (es)
SI (2) SI2368547T1 (es)
SM (2) SMT201200062B (es)
TN (2) TN2012000444A1 (es)
UA (1) UA102497C2 (es)
WO (1) WO2011117424A1 (es)
ZA (2) ZA201208116B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014009479B8 (pt) 2011-11-03 2019-01-29 Unilever Nv composição líquida de limpeza pessoal e método de desinfecção da superfície externa
CN104080340B (zh) 2011-12-06 2018-05-29 荷兰联合利华有限公司 抗微生物组合物
JP2015500817A (ja) 2011-12-06 2015-01-08 ユニリーバー・ナームローゼ・ベンノートシヤープ 抗菌剤組成物
CN104080341B (zh) 2011-12-06 2017-09-22 荷兰联合利华有限公司 抗微生物组合物
EP2866569B8 (en) 2012-06-27 2016-08-17 Unilever N.V. Antimicrobial composition
RU2533254C2 (ru) * 2012-12-29 2014-11-20 Федеральное государственное бюджетное учреждение научно-исследовательский институт детских инфекций Федерального медико-биологического агентства Способ лечения неврологических осложнений при ветряной оспе у детей
TWI463979B (zh) * 2013-04-12 2014-12-11 Nat Defense Medical Ct 檸檬醛用於製備治療局部腎絲球硬化症之藥物的用途
KR20150145314A (ko) 2014-06-18 2015-12-30 원광대학교산학협력단 카르본을 유효성분으로 포함하는 항균 조성물
CN106727628A (zh) * 2016-12-17 2017-05-31 郑州郑先医药科技有限公司 一种治疗慢性腹泻的西药组合物
KR101970281B1 (ko) * 2017-07-28 2019-04-18 고려대학교 산학협력단 리나릴 아세테이트를 포함하는 올메사탄으로 유발된 장운동과다증의 예방 또는 치료용 조성물
CN107648488A (zh) * 2017-09-29 2018-02-02 陈晓阳 一种用于治疗慢性咽炎的丸剂
KR102118181B1 (ko) * 2018-06-12 2020-06-02 광주여자대학교 산학협력단 식물성 정유를 유효성분으로 포함하는 a형 인플루엔자 바이러스에 대한 항바이러스 조성물
RU2707950C1 (ru) * 2018-11-28 2019-12-02 Общество с ограниченной ответственностью "ЭРБИ" Средство для обработки среды пребывания птицы на основе липосом с фитокомпозицией с иммунотропным действием и избирательным антисептическим эффектом и способ его применения
US20200179299A1 (en) * 2018-12-07 2020-06-11 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
CN110496117B (zh) * 2019-09-30 2022-09-06 中国科学院微生物研究所 一种小分子化合物在抗非洲猪瘟病毒感染中的新应用
CN111012769B (zh) * 2019-12-05 2021-02-12 青海大学 一种用于治疗包虫病的药物组合物、药物制剂及乳剂制备方法
WO2021224947A1 (en) * 2020-05-02 2021-11-11 Norouzi Mehdi Formulation of acute respiratory disease control formulation
CN114716327A (zh) * 2020-12-14 2022-07-08 中南民族大学 柏木醇衍生物、其制备方法及其应用
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
JP7133820B1 (ja) * 2021-06-09 2022-09-09 塩野香料株式会社 コロナウイルス感染症予防用香料組成物及び結合阻害剤
CN113994963B (zh) * 2021-09-26 2023-04-28 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种含有乙酸二氢香芹酯的抑芽剂及其用途
TWI800937B (zh) * 2021-10-01 2023-05-01 奇美醫療財團法人奇美醫院 用於治療登革熱病毒感染之方法
CN117338758B (zh) * 2023-12-06 2024-03-12 北京远大九和药业有限公司 一种药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5667M (es) 1966-03-10 1968-01-02
LU78955A1 (de) 1978-01-27 1979-09-06 Chimicasa Gmbh Verfahren zur inaktivierung von viren
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO2002056879A1 (en) * 2001-01-03 2002-07-25 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
KR20140103191A (ko) * 2005-11-30 2014-08-25 에덴 리서치 피엘씨 티몰, 유게놀, 게라니올, 시트랄, 및 ｌ―카르본에서 선택된 테르펜 또는 테르펜 혼합물을 포함하는 조성물 및 방법
US9403126B2 (en) * 2007-01-10 2016-08-02 The Regents Of The University Of Michigan Ultrafiltration membrane, device, bioartificial organ, and related methods
KR100796312B1 (ko) * 2007-05-23 2008-01-21 주식회사 바이오미스트테크놀로지 게라니얼，네랄 및 유게놀을 유효성분으로 함유하는 동물용소독제 조성물
KR100941595B1 (ko) 2008-06-05 2010-02-11 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 트리테르페노이드계 화합물
KR100950428B1 (ko) 2008-06-05 2010-04-02 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 디아릴헵타노이드계 화합물

Also Published As

Publication number Publication date
HK1176019A1 (en) 2013-07-19
NZ602602A (en) 2012-12-21
KR20120128716A (ko) 2012-11-27
CA2790087C (en) 2013-07-30
CY1115375T1 (el) 2017-01-04
ZA201208116B (en) 2014-04-30
BR112012024260A2 (pt) 2016-07-12
TN2012000444A1 (en) 2014-01-30
DK2368547T3 (da) 2013-01-02
SG184039A1 (en) 2012-10-30
DK2555763T3 (da) 2014-08-04
KR101340260B1 (ko) 2013-12-10
LU91805B1 (fr) 2011-09-26
MX2012010949A (es) 2013-01-29
UA102497C2 (ru) 2013-07-10
ZA201306926B (en) 2014-04-30
US20130225676A1 (en) 2013-08-29
PE20130065A1 (es) 2013-03-08
HRP20140706T1 (hr) 2014-09-12
SI2555763T1 (sl) 2014-08-29
EA025278B9 (ru) 2017-03-31
CY1119841T1 (el) 2018-06-27
TN2013000366A1 (en) 2015-01-20
AU2011231511B2 (en) 2014-03-20
AU2011231511A1 (en) 2012-10-18
EA201270749A1 (ru) 2013-03-29
BR112012024260B1 (pt) 2019-12-31
JP2013523622A (ja) 2013-06-17
EP2368547B1 (en) 2012-09-12
RS52544B (en) 2013-04-30
RS53435B (en) 2014-12-31
PT2555763E (pt) 2014-08-04
SMT201400104B (it) 2014-09-08
CL2012002606A1 (es) 2013-10-18
PE20141008A1 (es) 2014-09-20
ME02035B (me) 2013-04-30
PL2555763T3 (pl) 2014-09-30
EA025278B1 (ru) 2016-12-30
EP2555763B1 (en) 2014-04-30
HRP20120964T1 (en) 2012-12-31
CN102946876A (zh) 2013-02-27
PL2368547T3 (pl) 2013-02-28
JP5342085B2 (ja) 2013-11-13
US8883859B1 (en) 2014-11-11
CN102946876B (zh) 2016-04-06
PT2368547E (pt) 2012-11-20
HUE026121T2 (en) 2016-05-30
SI2368547T1 (sl) 2013-01-31
ES2486765T3 (es) 2014-08-19
MY153104A (en) 2014-12-31
ES2392938T3 (es) 2012-12-17
MA34074B1 (fr) 2013-03-05
EP2555763A1 (en) 2013-02-13
SMT201200062B (it) 2013-03-08
WO2011117424A1 (en) 2011-09-29
CO6602166A2 (es) 2013-01-18
MY158757A (en) 2016-11-15
EP2368547A1 (en) 2011-09-28
CY1113449T1 (el) 2016-06-22
IL222048A (en) 2014-09-30
US8980945B2 (en) 2015-03-17
CA2790087A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
TN2012000444A1 (en) Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
HN2011000072A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2012144754A3 (ko) 바이러스 억제 효능을 갖는 오배자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 조성물 및 이의 용도
WO2012104240A3 (de) Kosmetische verwendung
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл
NZ615613A (en) Viral inhibitor composition for in vivo therapeutic use
TH131426B (th) องค์ประกอบสารยับยั้งไวรัส (Viral inhibitor composition) สำหรับการใช้รักษา โรคภายในสิ่งมีชีวิตที่ประกอบด้วยการรวมของ (-)-คาร์โวน, (+)-คาร์โวน (Carvone), เจรานิออล (Geraniol) และ ส่วนประกอบน้ำมันที่จำเป็นนอกจากนี้
WO2011005043A3 (ko) 울금 추출물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
UA111158C2 (uk) Спосіб комбінованої терапії для лікування проліферативних захворювань
TH131426A (th) องค์ประกอบสารยับยั้งไวรัส (Viral inhibitor composition) สำหรับการใช้รักษาโรคภายในสิ่งมีชีวิตที่ประกอบด้วยการรวมของ (-)-คาร์โวน, (+)-คาร์โวน (Carvone), เจรานิออล (Geraniol) และ ส่วนประกอบน้ำมันที่จำเป็นนอกจากนี้

Legal Events

Date Code Title Description
FG Grant or registration